Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- 8-K Current report
- 3.1 Certificate of Designation of Preferences, Rights and Limitations of the Series a Convertible Voting Preferred Stock
- 4.1 Form of Specimen Stock Certificate for Series A-1 Preferred Stock
- 4.2 Form of Tranche a Warrant
- 4.3 Form of Tranche B Warrant
- 4.4 Form of Tranche C Warrant
- 10.1 Form of Securities Purchase Agreement, Dated March 3, 2023, by and Between Unicycive Therapeutics, Inc. and the Purchasers Named Therein
- 10.2 Placement Agency Agreement, Dated March 3, 2023 by and Between Unicycive Therapeutics, Inc. and Ef Hutton, Division of Benchmark Investments, LLC
- 99.1 Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb
- Download Excel data file
- View Excel data file
UNCY similar filings
- 10 Apr 23 Entry into a Material Definitive Agreement
- 31 Mar 23 Unicycive Announces Full Year 2022 Financial Results and Provides Business Update
- 30 Mar 23 Other Events
- 6 Mar 23 Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb
- 2 Mar 23 Other Events
- 7 Feb 23 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
- 2 Feb 23 Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea
Filing view
External links
Exhibit 4.1